• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Asia

BioWorld Asia

Nov. 2, 2021

View Archived Issues
deal-handshake2

Fosun Pharma acquires vaccine firm Antejin in deal worth up to $626M

Fosun Pharmaceutical Group Co. Ltd. has acquired a 73% stake of Antejin Biotech Co. Ltd. in a merger and acquisition deal worth up to ¥4.006 billion (US$626.2 million) to expand its pipeline in the field of bacterial vaccines. To kick off, Shanghai-based Fosun purchased about 32.52% equity interest in Antejin from nine shareholders for about ¥1.108 billion in cash. Read More

Shanghai Pharma out-licenses global rights for cancer drug in $292M Huya deal

Shanghai Pharmaceutical Holding Co. Ltd. out-licensed global rights of its antitumor small-molecule chemical drug, SPH-6162, to U.S.-based Huya Bioscience International LLC in a deal worth up to $292.5 million, plus a sales commission of 3% to 6%. Read More
Oral medication

Shouti raises $100M in series B round to turn injectable medicines into pills

Shouti Inc. raised $100 million in a series B round led by BVF Partners LP to advance its discovery platform for designing oral medicines and to speed up the development of its candidates. The Shanghai and California-based company has secured a total of $158 million in funding so far. Read More

Japan’s Aculys Pharma raises $60M in series A for sleep disorder candidate

Aculys Pharma Inc. closed its $60 million series A financing round, with the funds to be used to develop pitolisant (Wakix), a selective histamine H3 receptor antagonist/inverse agonist, in Japan. Read More

Antengene partners with Legochem Biosciences to co-develop ADCs

Antengene Corp. Ltd. has formed a partnership with Legochem Biosciences Inc. to jointly develop new antibody-drug conjugates (ADCs) primarily for cancer. The partners will integrate antibodies from Antengene with Legochem’s ADC technology. Read More
Australia map and flag with double helix

Ausbiotech 2021: Australia’s regenerative medicine sector ready for takeoff

PERTH, Australia – Investment in regenerative medicine in Australia in 2020 was AU$394.1 million (US295.8 million), accounting for nearly 23% of the overall capital invested in the Australian biotech sector, according to a new report published by Australia’s Regenerative Medicine Consortium. Read More

Bioplus Interphex Korea 2021: Plant-based vaccines, therapeutics could be way forward for COVID-19, future pandemics

Plants could be an alternative vaccine platform for both COVID-19 and future pandemics, shaking up a biologics sector that is currently mostly protein-based. South Korean company Bioapplications Inc., for example, is aiming to have a plant-derived booster shot for COVID-19 in the clinic in 2022. Read More

Appointments and advancements for Nov. 2, 2021

New hires and promotions in the biopharma industry in Asia-Pacific, including: I-Mab, Travecta. Read More

Financings for Nov. 2, 2021

Biopharmas in Asia-Pacific raising money in public or private financings: Hopstem, Lianbio, TC Biopharm Holdings. Read More

In the clinic for Oct. 26-Nov. 1, 2021

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: ABVC, Alphamab Oncology, Anheart, Arca, Astrazeneca, Canbridge, Cytodyn, Daiichi Sankyo, Hutchmed, Innovent Biologics, Meissa Vaccines, Moderna, Novatek, Olipass, Revive, Sorrento, Todos Medical, Vaxart, Vicore. Read More

Other news to note for Nov. 2, 2021

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Adagene, Canbridge, Curacle, Dania, Eisai, Eureka, Gabaeron, Gammadelta, Glaxosmithkline, Hannibal Innovation, Hibercell, Hitgen, Hummingbird, I-Mab, Imugene, Innovent Biologics, Mabylon, Medigen Vaccine Biologics, Merck, Moderna, Neocura Bio Medical Technology, Nippon Kayaku, Prism Biolab, Ridgeback, Scineuro, Sinopharm, Solasia, Takeda, Théa Open Innovation, Vernalis Research. Read More

Regulatory actions for Oct. 26-Nov. 1, 2021

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Akebia, Angel, Antengene, Axcella Health, Bharat Biotech International, Biontech, China Oncology Focus, Cocrystal, Coherus, Corvus, Gannex, Immunoforge, Immutep, Impact, Junshi, Merck, Moderna, Novavax, Ocugen, Oramed, Pfizer, RDIF, Recce, Ridgeback, Serum Institute of India, Serum Life Sciences, Sorrento, TFF, Vitti Labs. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe